Small-molecule modulators of the OX40OX40 ligand co-stimulatory proteinprotein interaction

Yun Song, Emilio Margolles-Clark, Allison L Bayer, Peter Buchwald

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

BACKGROUND AND PURPOSE The OX40OX40L proteinprotein interaction (PPI) is an important cell-surface signalling co-stimulatory regulator within the TNFR superfamily (TNFRSF) and a promising therapeutic target for immunomodulation. PPIs are difficult to modulate using small-molecules. Here, we describe the identification of a small-molecule OX40 modulator and confirm its partial agonist character.

EXPERIMENTAL APPROACH Cell-free screening assays were developed and used to identify OX40OX40L inhibitors. Modified versions of this assay were used to elucidate the binding partner and the binding nature of active compounds. OX40-transfected sensor cells with NF-κB reporters were constructed and used to confirm and characterize activity and specificity. Immunomodulatory activity and partial agonist nature were further confirmed by ex vivo T-cell polarization assays.

KEY RESULTS Several compounds that concentration-dependently affected OX40-OX40L were identified. Cell assays indicated that they were partial agonists with low micromolar potency and adequate selectivity. Under polarizing conditions based on TGF-β, the most promising compound mimicked the effect of an agonistic anti-OX40 antibody in suppressing regulatory T-cell generation and diverting CD4+CD62L+Foxp3-cells to TH9 phenotype in vitro.

CONCLUSIONS AND IMPLICATIONS We identified, to our knowledge, the first small-molecule compounds able to interfere with OX40OX40L binding and, more importantly, to act as partial agonists of OX40. This is particularly interesting, as small-molecule agonism or activation of PPIs is considered unusually challenging and there are only few known examples. These results provide proof-of-principle evidence for the feasibility of small-molecule modulation of the OX40OX40L interaction and for the existence of partial agonists for TNFRSF-PPIs.

Original languageEnglish
Pages (from-to)4955-4969
Number of pages15
JournalBritish Journal of Pharmacology
Volume171
Issue number21
DOIs
StatePublished - Jan 1 2014

Fingerprint

Ligands
Immunomodulation
Regulatory T-Lymphocytes
Anti-Idiotypic Antibodies
T-Lymphocytes
Phenotype
Therapeutics

ASJC Scopus subject areas

  • Pharmacology

Cite this

Small-molecule modulators of the OX40OX40 ligand co-stimulatory proteinprotein interaction. / Song, Yun; Margolles-Clark, Emilio; Bayer, Allison L; Buchwald, Peter.

In: British Journal of Pharmacology, Vol. 171, No. 21, 01.01.2014, p. 4955-4969.

Research output: Contribution to journalArticle

@article{daadf93244b7495d96626b7d7a891629,
title = "Small-molecule modulators of the OX40OX40 ligand co-stimulatory proteinprotein interaction",
abstract = "BACKGROUND AND PURPOSE The OX40OX40L proteinprotein interaction (PPI) is an important cell-surface signalling co-stimulatory regulator within the TNFR superfamily (TNFRSF) and a promising therapeutic target for immunomodulation. PPIs are difficult to modulate using small-molecules. Here, we describe the identification of a small-molecule OX40 modulator and confirm its partial agonist character.EXPERIMENTAL APPROACH Cell-free screening assays were developed and used to identify OX40OX40L inhibitors. Modified versions of this assay were used to elucidate the binding partner and the binding nature of active compounds. OX40-transfected sensor cells with NF-κB reporters were constructed and used to confirm and characterize activity and specificity. Immunomodulatory activity and partial agonist nature were further confirmed by ex vivo T-cell polarization assays.KEY RESULTS Several compounds that concentration-dependently affected OX40-OX40L were identified. Cell assays indicated that they were partial agonists with low micromolar potency and adequate selectivity. Under polarizing conditions based on TGF-β, the most promising compound mimicked the effect of an agonistic anti-OX40 antibody in suppressing regulatory T-cell generation and diverting CD4+CD62L+Foxp3-cells to TH9 phenotype in vitro.CONCLUSIONS AND IMPLICATIONS We identified, to our knowledge, the first small-molecule compounds able to interfere with OX40OX40L binding and, more importantly, to act as partial agonists of OX40. This is particularly interesting, as small-molecule agonism or activation of PPIs is considered unusually challenging and there are only few known examples. These results provide proof-of-principle evidence for the feasibility of small-molecule modulation of the OX40OX40L interaction and for the existence of partial agonists for TNFRSF-PPIs.",
author = "Yun Song and Emilio Margolles-Clark and Bayer, {Allison L} and Peter Buchwald",
year = "2014",
month = "1",
day = "1",
doi = "10.1111/bph.12819",
language = "English",
volume = "171",
pages = "4955--4969",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "21",

}

TY - JOUR

T1 - Small-molecule modulators of the OX40OX40 ligand co-stimulatory proteinprotein interaction

AU - Song, Yun

AU - Margolles-Clark, Emilio

AU - Bayer, Allison L

AU - Buchwald, Peter

PY - 2014/1/1

Y1 - 2014/1/1

N2 - BACKGROUND AND PURPOSE The OX40OX40L proteinprotein interaction (PPI) is an important cell-surface signalling co-stimulatory regulator within the TNFR superfamily (TNFRSF) and a promising therapeutic target for immunomodulation. PPIs are difficult to modulate using small-molecules. Here, we describe the identification of a small-molecule OX40 modulator and confirm its partial agonist character.EXPERIMENTAL APPROACH Cell-free screening assays were developed and used to identify OX40OX40L inhibitors. Modified versions of this assay were used to elucidate the binding partner and the binding nature of active compounds. OX40-transfected sensor cells with NF-κB reporters were constructed and used to confirm and characterize activity and specificity. Immunomodulatory activity and partial agonist nature were further confirmed by ex vivo T-cell polarization assays.KEY RESULTS Several compounds that concentration-dependently affected OX40-OX40L were identified. Cell assays indicated that they were partial agonists with low micromolar potency and adequate selectivity. Under polarizing conditions based on TGF-β, the most promising compound mimicked the effect of an agonistic anti-OX40 antibody in suppressing regulatory T-cell generation and diverting CD4+CD62L+Foxp3-cells to TH9 phenotype in vitro.CONCLUSIONS AND IMPLICATIONS We identified, to our knowledge, the first small-molecule compounds able to interfere with OX40OX40L binding and, more importantly, to act as partial agonists of OX40. This is particularly interesting, as small-molecule agonism or activation of PPIs is considered unusually challenging and there are only few known examples. These results provide proof-of-principle evidence for the feasibility of small-molecule modulation of the OX40OX40L interaction and for the existence of partial agonists for TNFRSF-PPIs.

AB - BACKGROUND AND PURPOSE The OX40OX40L proteinprotein interaction (PPI) is an important cell-surface signalling co-stimulatory regulator within the TNFR superfamily (TNFRSF) and a promising therapeutic target for immunomodulation. PPIs are difficult to modulate using small-molecules. Here, we describe the identification of a small-molecule OX40 modulator and confirm its partial agonist character.EXPERIMENTAL APPROACH Cell-free screening assays were developed and used to identify OX40OX40L inhibitors. Modified versions of this assay were used to elucidate the binding partner and the binding nature of active compounds. OX40-transfected sensor cells with NF-κB reporters were constructed and used to confirm and characterize activity and specificity. Immunomodulatory activity and partial agonist nature were further confirmed by ex vivo T-cell polarization assays.KEY RESULTS Several compounds that concentration-dependently affected OX40-OX40L were identified. Cell assays indicated that they were partial agonists with low micromolar potency and adequate selectivity. Under polarizing conditions based on TGF-β, the most promising compound mimicked the effect of an agonistic anti-OX40 antibody in suppressing regulatory T-cell generation and diverting CD4+CD62L+Foxp3-cells to TH9 phenotype in vitro.CONCLUSIONS AND IMPLICATIONS We identified, to our knowledge, the first small-molecule compounds able to interfere with OX40OX40L binding and, more importantly, to act as partial agonists of OX40. This is particularly interesting, as small-molecule agonism or activation of PPIs is considered unusually challenging and there are only few known examples. These results provide proof-of-principle evidence for the feasibility of small-molecule modulation of the OX40OX40L interaction and for the existence of partial agonists for TNFRSF-PPIs.

UR - http://www.scopus.com/inward/record.url?scp=84919360941&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919360941&partnerID=8YFLogxK

U2 - 10.1111/bph.12819

DO - 10.1111/bph.12819

M3 - Article

C2 - 24930776

AN - SCOPUS:84919360941

VL - 171

SP - 4955

EP - 4969

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 21

ER -